Status | Study |
Recruiting |
Study Name: Actis Total Hip System 2 Year Follow-up Condition: Osteoarthritis Traumatic Arthritis Rheumatoid Arthritis Date: 2016-05-23 Interventions: Device: Actis Total Hip System Total Hip Replacement and Hemi-hip Replacement |
Recruiting |
Study Name: Prediction of the Answer to the Treatment by Biotherapies for Naive Spondyloarthritis by Combinatorial Analysis of Serum Biomarkers Condition: Spondylitis, Ankylosing Date: 2016-05-11 Interventions: Drug: Etanercept ® 50 mg The etanercept is not the experimental study drug. Etanercept is a treatme |
Recruiting |
Study Name: Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis Condition: Ankylosing Spondyloarthritis Date: 2016-05-04 Interventions: Drug: Secukinumab Induction: 4 |
Recruiting |
Study Name: A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab (AIN457) to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis Condition: Ankylosing Spondylitis Date: 2016-05-03 Interventions: Biological: AIN457/Secukinumab |
Recruiting |
Study Name: The Effect of NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in the Spine in Ankylosing Spondylitis Condition: Ankylosing Spondylitis Date: 2016-04-20 Interventions: Biological: Golimumab Other Na |
Active, not recruiting |
Study Name: Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary Condition: Rheumatoid Arthritis Ankylosing Spondylitis Psoriatic Arth Date: 2016-04-13 |
Active, not recruiting |
Study Name: Comparative Clinical Trial to Evaluate Efficacy and Safety of BCD-055 and Remicade® in Patients With Ankylosing Spondylitis Condition: Ankylosing Spondylitis Date: 2016-04-04 Interventions: Biological: BCD-055 Other Name |
Active, not recruiting |
Study Name: Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis Condition: Ankylosing Spondylitis Date: 2016-04-04 Interventions: Drug: secukinumab 150mg Baseline, 1, 2, 3, 4 week. After 4 week, administered every 4 weeks. |
Active, not recruiting |
Study Name: Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis Condition: Ankylosing Spondylitis Date: 2016-04-03 Interventions: Drug: BCD-085 Other: Placebo |
Recruiting |
Study Name: UCB Cimzia Pregnancy Follow-up Study Condition: Rheumatoid Arthritis (RA) Crohn's Disease (CD) Psoriatic A Date: 2016-03-08 |